Open an account

Titan Pharmaceuticals

TTNP · NASDAQ

$4.61−$0.18 (−3.76%)TodayMarket closed ·
No price history for this range.

About TTNP

Titan Pharmaceuticals Inc is a US-based company operating in IT Services industry. The company is headquartered in New York City, New York. Titan Pharmaceuticals, Inc. is a pharmaceutical company. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.

Employees
4
Headquarters
New York City, New York
Listed
Jan 18, 1996
Sector
Information Technology
Industry
IT Services
Website
titanpharm.com

TTNP key statistics

Market cap
6.13M
Price-earnings ratio
—
Dividend yield
—
Average volume
3.36M
Volume
3.36M
Open price
$4.80
High today
$4.80
Low today
$4.55
52 Week high
$4.80
52 Week low
$4.55

Titan Pharmaceuticals (TTNP) at a glance

As of Oct 1, 2025, Titan Pharmaceuticals (TTNP) shares are priced at $4.61, giving the company a market cap of 6.13M.

Today the stock has traded between $4.55 and $4.80. The current price is 1.3% above the day's low and 4.0% below its high.

Volume so far is 3.36M shares, in line with the average of 3.36M shares a day.

Over the past year Titan Pharmaceuticals has ranged from $4.55 to $4.80, and now sits 24% of the way up that range.

Titan Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q3 FY21 it reported -$3.80 per share against an estimate of -$7.14.

TTNP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 37.2% on average.

  1. Q3 FY19: reported -$108.00 per share against an estimate of -$131.58
  2. Q4 FY19: reported -$48.00 per share against an estimate of -$48.96
  3. Q2 FY20: reported -$30.00 per share against an estimate of -$21.42
  4. Q3 FY20: reported -$30.00 per share against an estimate of -$21.42
  5. Q4 FY20: reported -$17.20 per share against an estimate of -$27.13
  6. Q1 FY21: reported -$5.60 per share against an estimate of -$17.34
  7. Q2 FY21: reported -$3.40 per share against an estimate of -$7.14
  8. Q3 FY21: reported -$3.80 per share against an estimate of -$7.14

TTNP news

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releaseBusiness Wire

    TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE, SPTN, TTNP on Behalf of Shareholders

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate Merger of TTNP, BASE, SPTN, and CFSB

  • Press releasePRNewswire

    SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: TCBC, CIO, TTNP, and VBTX

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, LNSR, ICAD on Behalf of Shareholders

  • Rishabh Mishra

    US Stocks Likely To Open Higher: Expert Says 'The Selling Pressure Is Starting To Be Exhausted'

Similar companies

Companies in the same industry as Titan Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.